Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
5.58
-1.29 (-18.78%)
At close: Dec 5, 2025, 4:00 PM EST
5.73
+0.15 (2.69%)
After-hours: Dec 5, 2025, 5:25 PM EST
Protara Therapeutics Employees
As of December 31, 2024, Protara Therapeutics had 33 total employees, including 28 full-time and 5 part-time employees. The number of employees increased by 6 or 22.22% compared to the previous year.
Employees
33
Change (1Y)
6
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,603,061
Market Cap
215.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33 | 6 | 22.22% |
| Dec 31, 2023 | 27 | 2 | 8.00% |
| Dec 31, 2022 | 25 | -6 | -19.35% |
| Dec 31, 2021 | 31 | 4 | 14.81% |
| Dec 31, 2020 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TARA News
- 20 hours ago - Protara Announces Pricing of $75 Million Public Offering - GlobeNewsWire
- 1 day ago - Protara Announces Proposed Public Offering - GlobeNewsWire
- 1 day ago - Protara Therapeutics: End Of 2025 Proving Eventful Indeed - Seeking Alpha
- 2 days ago - Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript - Seeking Alpha
- 2 days ago - Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - GlobeNewsWire
- 4 days ago - Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - GlobeNewsWire
- 16 days ago - Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript - Seeking Alpha
- 16 days ago - Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - GlobeNewsWire